Liqing Zhou

439 citations
23 papers · 366 indexed · h-index 11
Topics
Epigenetics and DNA Methylation (5 papers)Cancer-related Molecular Pathways (4 papers)Esophageal Cancer Research and Treatment (3 papers)

In The Last Decade

Liqing Zhou

22 papers receiving 363 citations

Peers

Liqing Zhou
Comparison fields: 5 of 52
  • Molecular Biology 246
  • Cancer Research 121
  • Oncology 102
  • Pathology and Forensic Medicine 68
  • Pulmonary and Respiratory Medicine 47
Replace Eva Galle with:
Eva Galle Belgium
Chih Yi Chen Taiwan
Yinan Guo China
Aizhong Shao China
Daniel Onofre Vidal Brazil
Marcin Szaumkessel Poland
Shanqi Xu China
Liqiang Wang China
Juan Ramón Delgado Spain
Suenori Chiku Japan
Liqing Zhou relative to Eva Galle Belgium Eva Galle's profile →
Citations per field
00.5×6.2×
Eva Galle · 1×
Citations per year

Countries citing papers authored by Liqing Zhou

Since Specialization
Citations

This map shows the geographic impact of Liqing Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liqing Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liqing Zhou more than expected).

Fields of papers citing papers by Liqing Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liqing Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liqing Zhou. The network helps show where Liqing Zhou may publish in the future.

Co-authorship network of co-authors of Liqing Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Liqing Zhou. A scholar is included among the top collaborators of Liqing Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liqing Zhou. Liqing Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 3
3 6
4 2
5 4
6 16
7 24
8 27
9 5
10 9
11 10
12 25
13 5
14 21
15 11
16 43
17 63
18 23
19 27
20
GC Glu416Asp and Thr420Lys polymorphisms contribute to gastrointestinal cancer susceptibility in a Chinese population.
28

About Liqing Zhou

Liqing Zhou is a scholar working on Oncology, Hepatology and Pathology and Forensic Medicine, having authored 23 papers that have together received 366 indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (5 papers), Cancer-related Molecular Pathways (4 papers) and Esophageal Cancer Research and Treatment (3 papers). The work is most often cited by research in Cancer Research (121 citations), Pathology and Forensic Medicine (68 citations) and Oncology (102 citations). Liqing Zhou has collaborated with scholars based in China, United Kingdom and South Korea. Frequent co-authors include Ming Yang, Qipeng Yuan, Xiaohu Tang, Changchun Zhou, Chao Lu, Xiaojiao Zhang, Juan Shi, Ziqiang Li, Hui Zhu and Jupeng Yuan. Their work appears in journals such as PLoS ONE, Scientific Reports and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026